VANCOUVER, BC — May 1, 2026 — Leads & Copy — VVT Med Inc. (TSXV: VVTM) has announced that the British Columbia Securities Commission (BCSC) has granted a temporary management cease trade order (MCTO) regarding the delay in filing its annual financial statements.
The delay includes management’s discussion and analysis and related officer certifications for the financial year ended December 31, 2025, collectively known as the “Required Filings.” The initial announcement regarding the application for the MCTO was made on April 17, 2026.
According to the company, the MCTO does not prevent shareholders who are not employees or insiders from trading their securities. However, it prohibits the chief executive officer and the chief financial officer from trading in the company’s securities until the Required Filings are submitted.
Additionally, VVT Med Inc. is restricted from issuing securities or acquiring them from insiders or employees, except under legally binding obligations existing as of May 1, 2026, until the filings are completed.
The company attributes the delay to external circumstances, specifically the ongoing armed conflict in the Middle East, which has disrupted operational and administrative processes needed to finalize the annual reporting and audit. These disruptions include restricted access to essential resources and personnel in Israel, affecting both the company and its service providers.
VVT Med Inc. has committed to completing the Required Filings as soon as possible, clarifying that the delay is administrative, not due to disagreements with auditors, and that there are no material uncertainties regarding the company’s financial position. The company anticipates rectifying the default by filing on or before June 29, 2026, at which point the MCTO will be lifted.
In compliance with National Policy 12-203, VVT Med Inc. will issue bi-weekly status updates via news releases until the Required Filings are submitted. The company stated that it does not foresee any additional specified defaults under NP 12-203. As of the date of the release, there are no insolvency proceedings against the company, and all other material information has been disclosed.
VVT Med Inc. also confirms that it is current with all other filing obligations.
VVT is the only FDA-cleared, standalone company offering non-thermal, non-tumescent (NT-NT) varicose vein treatment technology. VVT’s catheter-based technologies, ScleroSafe and V-Block, enable safe, office-based procedures with no anesthesia or downtime. Addressing the widest range of vein diameters, VVT’s solutions empower physicians to treat both the medical and aesthetic aspects of vein disease via a cost-efficient, simultaneous sclerosant injection and blood aspiration process. The Company’s patented technology portfolio includes 55 patents from 14 patent families across 20 countries, providing broad global intellectual property protection through 2038.
Source: VVT Med Inc.
